UCB and Accenture Collaborate to Accelerate Data Processing and Help Improve Patient Safety
NEW YORK; Dec 16, 2019 – Accenture (NYSE:ACN) and UCB, a global biopharmaceutical company, have collaborated to build a safety solution based on Accenture’s INTIENT™ Pharmacovigilance to accelerate processing of individual patient safety case reports. This will help UCB uncover patient safety impacts from existing treatments and better manage the risks of new drugs and services.
Comments
Post a Comment